Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299841 | 0.78 | HTT (0.37) | HTTSMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL16474376 | 0.78 | HTT (0.33) | HTTSMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL12507686 | 0.76 | NPC1 (0.49) | HTTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL17045437 | 0.76 | RECQL (0.36) | HTTSMN1; SMN2NPC1ALDH1A1KDM4E | |
| SCHEMBL19592225 | 0.76 | L3MBTL1 (0.41) | HTTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL23400503 | 0.76 | HTT (0.36) | HTTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL13255976 | 0.76 | RAB9A (0.35) | HTTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL20050020 | 0.72 | PAK4 (0.34) | — | |
| SCHEMBL29578926 | 0.72 | — | — | |
| SCHEMBL20086655 | 0.72 | MPO (0.35) | HTTSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | HTT 3484/4885SMN1; SMN2 2486/4885NPC1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.